ChiCTR2000038585 版本V1.1 版本创建时间2020/11/30 11:15:29 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000038585 

最近更新日期:

Date of Last Refreshed on:

2020-09-24 13:28:31 

注册时间:

Date of Registration:

2020-09-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

心脏手术术后新型多模式镇痛与传统阿片类药物镇痛的镇痛效果及预后比较

Public title:

Multimodal analgesia versus traditional opiate based analgesia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

心脏手术术后新型多模式镇痛与传统阿片类药物镇痛的镇痛效果及预后比较

Scientific title:

Multimodal analgesia versus traditional opiate based analgesia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

金琳 

研究负责人:

金琳 

Applicant:

Lin Jin 

Study leader:

Lin Jin 

申请注册联系人电话:

Applicant telephone:

+86 13917131195

研究负责人电话:

Study leader's telephone:

+86 13917131195

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jin.lin@zs-hospital.sh.cn

研究负责人电子邮件:

Study leader's E-mail:

jin.lin@zs-hospital.sh.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市徐汇区斜土路1609号16号楼4楼心血管手术中心

研究负责人通讯地址:

上海市徐汇区斜土路1609号16号楼4楼心血管手术中心

Applicant address:

Cardiovascular Surgery Center, Forth Floor, Building 16, 1609 Xietu Road, Xuhui District, Shanghai

Study leader's address:

Cardiovascular Surgery Center, Forth Floor, Building 16, 1609 Xietu Road, Xuhui District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

复旦大学附属中山医院

Applicant's institution:

Zhongshan Hospital, Fudan University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

B2018-039R

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

复旦大学附属中山医院伦理委员会

Name of the ethic committee:

Ethics Committee of Zhongshan Hospital, Fudan University

伦理委员会批准日期:

Date of approved by ethic committee:

2018-04-17 00:00:00

伦理委员会联系人:

杨梦婕

Contact Name of the ethic committee:

Mengjie Yang

伦理委员会联系地址:

上海市徐汇区枫林路180号复旦大学附属中山医院5号楼412室

Contact Address of the ethic committee:

Room 412, Building 5, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Xuhui District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

复旦大学附属中山医院

Primary sponsor:

Zhongshan Hospital, Fudan University

研究实施负责(组长)单位地址:

上海市徐汇区枫林路180号

Primary sponsor's address:

180 Fenglin Road, Xuhui District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属中山医院

具体地址:

徐汇区枫林路180号

Institution
hospital:

Zhongshan Hospital, Fudan University

Address:

180 Fenglin Road, Xuhui District

经费或物资来源:

自筹

Source(s) of funding:

Self-financing

Target disease:

Cardiac-Vascular Surgery

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价与传统芬太尼族或吗啡类药物镇痛相比,心脏手术后复合使用对乙酰氨基酚、氯胺酮、利多卡因、右美托咪啶的少阿片类药物多模式镇痛方案是否能够提供更好的镇痛效果、减少不良反应、改善预后。  

Objectives of Study:

To evaluate if an opiate sparing multimodal regimen of tylenol, gabapentin, ketamine, lidocaine and dexmedetomidine provided better analgesic effect, less side effects (PONV) and improved cardiac surgery outcome compared to a traditional fentanyl and hydromorphine regimen after cardiac surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.性别不限,年龄在18岁到80岁之间; 2.ASA分级II-III级; 3.体重指数(BMI)18-31; 4.择期正中开胸体外循环下心脏手术; 5.自愿参加并签署知情同意书。

Inclusion criteria

1.Aged 18 to 80years, no limit on the gender; 2.American Society of Anaesthesiologists (ASA) Score II-III; 3.Body mass index (BMI) of 18 to 31; 4.Elective on-pump cardiac surgery through median sternotomy; 5.Written informed consent.

排除标准:

1.同时参加其他临床试验者; 2.不配合或无法沟通的患者; 3.深低温停循环手术; 4.二次手术患者; 5.术前肝肾功能不全、凝血功能异常患者 6.已知滥用酒精、药物或麻醉品者; 7.处于怀孕期或哺乳期的女性患者;8.预计生存期小于24 h。

Exclusion criteria:

1.Participating in other clinical trials at the same time; 2.Patients who are unable to cooperate or communicate; 3.Deep Hypothermic Circulatory Arrest; 4.Patients undergoing secondary surgery; 5.Patients with liver, kidney or coagulation insufficiency before operation; 6.Known abusers of alcohol, drugs or narcotics; 7.Women who are pregnant or nursing; 8.expected survival less than 24 h.

研究实施时间:

Study execute time:

From 2020-10-01 00:00:00 To 2021-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-01 00:00:00 To 2020-11-30 00:00:00  

干预措施:

Interventions:

组别:

试验组

样本量:

75

Group:

experimental group

Sample size:

干预措施:

多模式镇痛

干预措施代码:

Intervention:

Multimodal analgesia

Intervention code:

组别:

对照组

样本量:

75

Group:

control group

Sample size:

干预措施:

传统阿片类药物镇痛

干预措施代码:

Intervention:

traditional opiate based analgesia

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海市 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

复旦大学附属中山医院 

单位级别:

三甲医院 

Institution
hospital:

Zhongshan Hospital, Fudan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

镇痛效果

指标类型:

主要指标

Outcome:

Analgesic effect

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阿片类药物用量

指标类型:

次要指标

Outcome:

Additional opioid consumption

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后谵妄

指标类型:

次要指标

Outcome:

postoperative delirium

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

急性肾功能不全

指标类型:

次要指标

Outcome:

Incidence of acute kidney injury

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后恶心呕吐

指标类型:

次要指标

Outcome:

PONV

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血糖异常

指标类型:

次要指标

Outcome:

Dysglycemia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

机械通气时间

指标类型:

次要指标

Outcome:

mechanical ventilation time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ICU停留时间

指标类型:

次要指标

Outcome:

ICU stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间

指标类型:

次要指标

Outcome:

Hospital stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

系统免疫炎症指数

指标类型:

次要指标

Outcome:

The systemic immune-inflammation index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由第三方使用SPSS软件生成随机数字表产生随机序列.

Randomization Procedure (please state who generates the random number sequence and by what method):

Random sequence generated by a third party according to random number table method with SPSS software.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

网上平台

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Online platform

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录,收据收集有专门的参与人员完成,及时登记收集数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case records, receipts collected by special participants, timely registration and collection of data

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-09-24 13:28:27